AirPhysio Oscillating Positive Expiratory Pressure OPEP Device for Average Lung Capacity
The AirPhysio Average Lung Capacity is designed for most teenagers and adults who don’t have any severe lung conditions. This device has the potential to help slow down the progression and improve respiratory conditions like asthma, COPD, Bronchiectasis, cystic fibrosis, etc… Unless you have a severe lung condition or very low lung capacity, this version of AirPhysio is the recommended version for most people.
The AirPhysio device has the following registrations: TGA (Australia), FDA (USA), CE (Europe), SFDA (Saudi Arabia), MFDS (Korea) DAV (Vietnam) and is Medsafe WAND notified in NZ (with our sister company – Apex Medical). It is also a Pharmac listed device.
Medical compliance is not just the legal requirements in healthcare; they are also the critical components to safe, quality patient care and is a focal goal here at AirPhysio. Due to the drastic increase in demand on an international level, achieving these certifications in our major export locations is a big step. After a 3 year-long process, a major goal was achieved - the approval of the US FDA. The FDA's standpoint is to protect the public with particular scopes on safety and efficacy when approving a product. The importance of the AirPhysio device being approved by the FDA shows that it has undergone a rigorous quality system process and review in a nation with such a vast global influence. AirPhysio now having this improved credibility and rapport with the FDA assists with the companies endeavour for global awareness to help improve the lives of all those suffering from respiratory conditions including; Asthma, COPD, Emphysema, Bronchitis, Cystic Fibrosis and other conditions producing retained secretions. To also improve the everyday individual's lung capacity and function our introduced sliding scale device range includes 4 devices ranging from children to athlete, everyone has an opportunity for naturally better breathing. Check out our range below.